Found: 25
Select item for more details and to access through your institution.
Modulation of peritumoral fibroblasts with a membrane-tethered tissue inhibitor of metalloproteinase (TIMP) for the elimination of cancer cells.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 198, doi. 10.1007/s10637-021-01177-4
- By:
- Publication type:
- Article
Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 1, doi. 10.1007/s10637-021-01158-7
- By:
- Publication type:
- Article
Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 21, doi. 10.1007/s10637-021-01173-8
- By:
- Publication type:
- Article
Reforms of regulatory pathways for approval of new antineoplastic drugs in Japan from 2004 to 2019 and accompanying changes in pivotal clinical trial designs.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 142, doi. 10.1007/s10637-021-01165-8
- By:
- Publication type:
- Article
Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 182, doi. 10.1007/s10637-021-01162-x
- By:
- Publication type:
- Article
Author Correction: Antineoplastic activity of products derived from cellulose‑containing materials: levoglucosenone and structurally‑related derivatives as new alternatives for breast cancer treatment.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 124, doi. 10.1007/s10637-021-01184-5
- By:
- Publication type:
- Article
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 115, doi. 10.1007/s10637-021-01175-6
- By:
- Publication type:
- Article
A comprehensive analysis of different gene classes in pancreatic cancer: SIGLEC15 may be a promising immunotherapeutic target.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 58, doi. 10.1007/s10637-021-01176-5
- By:
- Publication type:
- Article
A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 81, doi. 10.1007/s10637-021-01164-9
- By:
- Publication type:
- Article
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 134, doi. 10.1007/s10637-021-01170-x
- By:
- Publication type:
- Article
Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 10, doi. 10.1007/s10637-021-01169-4
- By:
- Publication type:
- Article
Antineoplastic activity of products derived from cellulose-containing materials: levoglucosenone and structurally-related derivatives as new alternatives for breast cancer treatment.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 30, doi. 10.1007/s10637-021-01167-6
- By:
- Publication type:
- Article
Successful treatment of a case of hormone receptor–positive metastatic extramammary Paget disease with tamoxifen.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 194, doi. 10.1007/s10637-021-01168-5
- By:
- Publication type:
- Article
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 190, doi. 10.1007/s10637-021-01166-7
- By:
- Publication type:
- Article
Anaphylactic shock in a small cell lung cancer patient receiving atezolizumab therapy: a rare but potentially fatal complication.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 209, doi. 10.1007/s10637-021-01163-w
- By:
- Publication type:
- Article
In vitro selection of DNA aptamers against human osteosarcoma.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 172, doi. 10.1007/s10637-021-01161-y
- By:
- Publication type:
- Article
KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non‐small cell lung cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 43, doi. 10.1007/s10637-021-01159-6
- By:
- Publication type:
- Article
Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 157, doi. 10.1007/s10637-021-01157-8
- By:
- Publication type:
- Article
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 68, doi. 10.1007/s10637-021-01156-9
- By:
- Publication type:
- Article
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 106, doi. 10.1007/s10637-021-01155-w
- By:
- Publication type:
- Article
Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 151, doi. 10.1007/s10637-021-01154-x
- By:
- Publication type:
- Article
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 99, doi. 10.1007/s10637-021-01153-y
- By:
- Publication type:
- Article
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 163, doi. 10.1007/s10637-021-01143-0
- By:
- Publication type:
- Article
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 91, doi. 10.1007/s10637-021-01142-1
- By:
- Publication type:
- Article